Equities Analysts Set Expectations for HRTX Q4 Earnings

Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Investment analysts at Northland Capmk decreased their Q4 2024 earnings estimates for Heron Therapeutics in a report issued on Tuesday, November 12th. Northland Capmk analyst C. Byrnes now expects that the biotechnology company will earn ($0.03) per share for the quarter, down from their prior estimate of ($0.02). The consensus estimate for Heron Therapeutics' current full-year earnings is ($0.08) per share.

HRTX has been the subject of several other reports. Needham & Company LLC lowered their target price on shares of Heron Therapeutics from $5.00 to $4.00 and set a "buy" rating for the company in a research note on Wednesday. StockNews.com raised shares of Heron Therapeutics from a "hold" rating to a "buy" rating in a research note on Wednesday.

Heron Therapeutics Price Performance

HRTX traded down $0.05 during midday trading on Friday, reaching $1.19. 1,496,794 shares of the company's stock were exchanged, compared to its average volume of 2,418,683. The business's 50-day moving average price is $1.82 and its 200 day moving average price is $2.51. The stock has a market capitalization of $181.00 million, a PE ratio of -6.61 and a beta of 1.81. Heron Therapeutics has a 1-year low of $0.81 and a 1-year high of $3.93.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.03). The business had revenue of $32.81 million for the quarter, compared to analysts' expectations of $36.40 million. During the same period last year, the company posted ($0.17) earnings per share.

Hedge Funds Weigh In On Heron Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. nVerses Capital LLC acquired a new position in Heron Therapeutics during the second quarter valued at approximately $27,000. Headlands Technologies LLC acquired a new position in Heron Therapeutics in the first quarter valued at about $30,000. Susquehanna Fundamental Investments LLC bought a new position in Heron Therapeutics in the 1st quarter valued at $32,000. HB Wealth Management LLC acquired a new position in Heron Therapeutics during the 2nd quarter worth about $35,000. Finally, Cutter & CO Brokerage Inc. acquired a new position in shares of Heron Therapeutics during the third quarter worth approximately $39,000. Institutional investors own 80.01% of the company's stock.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.